EXHIBIT 99.1
[LOGO]
N E W S R E L E A S E
For Immediate Release
Contact: HemaCare Corporation
JoAnn Stover, Director of Investor Relations
877.310.0717
www.hemacare.com
HEMACARE ADDS NEW MEMBERS TO ITS BOARD OF DIRECTORS
- -----------------------------------------------------------------
Los Angeles, CA, May 19, 2003 - HemaCare Corporation (OTC
Bulletin Board: HEMA) announced the appointment of Wm. Andrew L.
Heaton, M.D. and Terry Van Der Tuuk to its Board of Directors.
Wm. Andrew L. Heaton, M.D. serves as Vice President of
Regulatory/Scientific Affairs and Chief Medical Officer of
Chiron, Blood Testing Division, an international provider of
nucleic acid and immuno testing to the blood screening market.
Prior to assuming his position at Chiron, Dr. Heaton was Chief
Medical Officer of Blood Systems Foundation and President and
Chief Executive Officer of the Blood Centers of the Pacific.
Dr. Heaton is a nationally recognized expert in both the medical
and technical fields of blood banking and has published numerous
articles in the fields of pathology, hematology and blood
banking.
Terry Van Der Tuuk is Vice Chairman of Graphic Technology, a
barcode label company which was listed on the American Stock
Exchange and sold to Nitto Denko Corporation in 1989. He is also
Chairman of Mid-America Merchandising, Inc., a promotional
products company, and Founder and President of VanKan, Inc., a
Kansas based venture capital firm, which invests in privately
held companies in the Midwest area.
Jay Steffenhagen, Chairman of HemaCare Corporation said,
"This is a transitional period as we move toward profitability,
and HemaCare is fortunate to have these two accomplished
individuals available to help establish strategy and guide us
toward the future. We are looking forward to the benefit of
Andrew Heaton's experience and knowledge in the medical and blood
banking fields and Terry Van Der Tuuk's broad business
background."
- more -
About HemaCare Corporation
Founded in 1978, HemaCare is a national provider of blood
products and services and the only publicly traded company
engaged in the blood services industry in the U.S. HemaCare is
licensed by the FDA and accredited by the American Association of
Blood Banks. The Company focuses on providing cost effective,
high quality solutions to the blood-related needs of U.S.
hospitals.
This press release contains "forward-looking statements" within
the meaning of the term in the Private Securities Litigation
Reform Act of 1995 (Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934,
as amended). Additional written or oral forward-looking
statements may be made by the Company from time to time in
filings with the Securities and Exchange Commission or otherwise.
Statements contained herein that are not historical facts are
forward-looking statements pursuant to the safe harbor provisions
referenced above. Forward-looking statements are inherently
subject to risks and uncertainties some of which cannot be
predicted or quantified. Such risks and uncertainties include,
without limitation, the risks and uncertainties set forth from
time to time in reports filed by the Company with the Securities
and Exchange Commission. Although the Company believes that the
expectations reflected in such forward-looking statements are
reasonable, it can give no assurance that such expectations will
prove to be correct. Consequently, future events and actual
results could differ materially from those set forth in, or
contemplated by, the forward-looking statements contained herein.
The Company undertakes no obligation to publicly release any
revision to these forward-looking statements made to reflect
events or circumstances after the date hereof.
###